Kineta Completes Reverse Merger with Yumanity Therapeutics
SEATTLE, Dec. 19 (Korea Bizwire) — Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today the completion of its reverse merger with Yumanity Therapeutics, Inc. (“Yumanity”). The combined company will operate under the name Kineta, Inc. and its shares will commence trading [...]